French pharmaceutical company Sanofi SA (SAN.FR) and Transgene
SA (TNG.FR) Monday said they signed an agreement for the creation
of an industrial platform dedicated to the production of
immunotherapy products.
MAIN FACTS:
- The platform will be realized on Genzyme Polyclonals site in
Lyon - Gerland area for an investment amount of 10 million euro
equally financed by Sanofi and Transgene. The Platform will remain
Sanofi's exclusive property.
- "Transgene is extremely pleased to announce this agreement
with the Sanofi Group, as it combines the strong expertise of
recognized experts and pioneers in the fields of gene therapy and
vaccines," said Philippe Archinard, Chairman and Chief Executive
Officer of Transgene.
- "The Lyon area is a strategic place for Sanofi in the field of
immunology, and I am extremely pleased to announce this
collaboration with Transgene, representing a total investment of 10
million euros on Genzyme Polyclonals site in the Lyon Gerland
area," said Olivier Charmeil, President and CEO of Sanofi
Pasteur.
-Write to Inti Landauro at inti.landauro@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires